NEW YORK and CAMBRIDGE, England, May 1, 2025 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancers, presented data from a ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be effective for patients with metastatic colorectal cancer (CRC) refractory to ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...